Project Title: Identifying most effective treatment strategies to control Arterial Hypertension in Sub Saharan Africa- A Randomized Controlled Trial

Project Description: The rollout of antiretroviral treatment (ART) has led to dramatic reduction in HIV/AIDS-associated deaths. With increased life expectancy, HIV positive individuals are at increased risk of cardiovascular diseases. The double burden of HIV and arterial hypertension the most prevalent risk factor for cardiovascular diseases in sub Saharan Africa-is a major challenge especially in rural areas due to low awareness in communities, lack of screening programs, high cost of antihypertensive medications and general lack of evidence... The rollout of antiretroviral treatment (ART) has led to dramatic reduction in HIV/AIDS-associated deaths. With increased life expectancy, HIV positive individuals are at increased risk of cardiovascular diseases. The double burden of HIV and arterial hypertension the most prevalent risk factor for cardiovascular diseases in sub Saharan Africa-is a major challenge especially in rural areas due to low awareness in communities, lack of screening programs, high cost of antihypertensive medications and general lack of evidence regarding optimal recommends starting treatment for Africans living in sub Saharan Africa. The World Health Organization (WHO) recommends starting treatment of arterial hypertension with a thiazide diuretic (TZD) or a calcium channel blocker (CCB) and dual combination If the target blood pressure is not achieved. Newer antihypertensive drugs and treatment strategies are available but have not been compared to the WHO approach in Africa. With the proposed randomized controlled 2- center trial, we aim at closing this evidence gap, comparing two combination treatment strategies with the WHO standards aiming at rapid control of arterial hypertension: a dual combination of a CCB and an angiotensin II receptor blocker (ARB) starting at half dose) and triple combination of CCB, TZD, and ARB starting at a quarter dose with optional dose titration after 4 and 8 weeks, if target blood pressure is not reached. Read more

Principal Investigator : Herry Mapesi

Department Name : BRCT

Time frame: (2019-10-01) - (2022-12-31)

Funding Partners
University Hospital Basel (Normal)
External Collaborating Partners
None added yet.